Establishment and characterization of an ovarian yolk sac tumor cell line reveals possible involvement of Nkx2.5 in tumor development

Oncology

Volumn 74, Issue 1-2, 2008, Pages 104-111

  Shibata, Kiyosumi ^a   Kajiyama, Hiroaki ^a   Yamamoto, Eiko ^a   Terauchi, Mikio ^a   Ino, Kazuhiko ^a   Nawa, Akihiro ^a   Kikkawa, Fumitaka ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cisplatin; Germ cell tumors; Nkx2.5; NOY1; Ovarian yolk sac tumor; Tumor cell lines; Yolk sac

Indexed keywords

TRANSCRIPTION FACTOR NKX2.5;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CHROMOSOME ANALYSIS; CONTROLLED STUDY; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OVARY TUMOR; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; TUMOR CELL LINE; TUMOR GROWTH; YOLK SAC TUMOR;

ADULT; ANIMALS; CELL LINE, TUMOR; ENDODERMAL SINUS TUMOR; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; MICE; MICE, NUDE; OVARIAN NEOPLASMS; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TRANSPLANTATION, HETEROLOGOUS;

EID: 46249132635     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000139138     Document Type: Article

References (27)

1. Quirk JT, Natarajan N: Ovarian cancer incidence in the United States, 1992-1999. Gynecol Oncol 2005;97:519-523.
2. Gershenson DM: Update on malignant ovarian germ cell tumors. Cancer 1993;71(4 suppl):1581-1590.
3. Willemse PHB, Aalders JG, Bouma J, et al: Long-term survival after vinblastine, bleomycin, and cisplatin treatment in patients with germ cell tumors in the ovary: an update. Gynecol Oncol 1987;28:268-277.
4. Lai CH, Chang TC, Hsueh S, et al: Outcome and prognostic factors in ovarian germ cell malignancies. Gynecol Oncol 2005;96:784-791.
5. Billmire D, Vinocur C, Rescrla F, et al: Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: An Intergroup Study. J Pediatr Surg 2004;39:424-429.
6. Zanetta G, Bonazzi C, Cantu M, et al: Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol 2001;19:1015-1020.
7. Zanagnolo V, Sartori E, Galleri G, et al: Clinical review of 55 cases of malignant ovarian germ cell tumors. Eur J Gynaecol Oncol 2004;25:315-320.
8. Williams S, Blessing JA, Liao SY, et al: Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin. J Clin Oncol 1994;12:701-706.
9. Skof E, Grasic Kuhar C, Cerar O, et al: Survival and fertility of patients with malignant ovarian germ cell tumors. Eur J Gynaecol Oncol 2004;25:702-706.
10. Murgaesu N, Schmid P, Dancey G, et al: Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol 2006;24:4862-4866.
11. Nichols CR: Ifosfamide in the treatment of germ cell tumors. Semin Oncol 1996;23(3 suppl 6):65-73.
12. Motzer RJ, Bajorin DF, Schwartz LH, et al: Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 1994;12:2277-2283.
13. Einhorn LH, Stender MJ, Williams SD: Phase II trial of gemcitabine in refractory germ cell tumors. J Clin Oncol 1999;17:509-511.
14. Maas K, Daikeler T, Kanz L, Bokemeyer C: Activity of gemcitabine in platinum resistant ovarian germ cell cancer. Eur J Cancer 1996;32:1437-1438.
15. Mitchell PL, Al-Nasiri N, A'Hern R, et al: Treatment of nondysgerminomatous ovarian germ cell tumors. Cancer 1999;85:2232-2244.
16. Mayordomo JI, Paz-Ares L, Rivera F, et al: Ovarian and extragonadal malignant germ cell tumors in females: a single-institution experience with 43 patients. Ann Oncol 1994;5:225-231.
17. Gorog D, Regoly-Merei J, Paku S, et al: Alpha-fetoprotein expression is a potential prognostic marker in hepatocellular carcinoma. World J Gastroenterol 2005;11:5015-5018.
18. Komuro I, Izumo S: Csx: a murine homeobox-containing gene specifically expressed in the developing heart. Proc Natl Acad Sci USA 1993;90:8145-8149.
19. Chen CY, Schwartz RJ: Identification of novel DNA binding targets and regulatory domains of a murine tinman homeodomain factor, nkx-2.5. J Biol Chem 1995;270:15628-15633.
20. Aperqis GA, Crawford N, Ghosh D, et al: A novel nk-2 related transcription factor associated with human fetal liver and hepatocellular carcinoma. J Biol Chem 1998;273:2917-2925.
21. Kajiyama Y, Tian J, Locker J: Regulation of alpha-fetoprotein expression by Nkx2.8. Mol Cell Biol 2002;22:6122-6130.
22. Suzuki Y, Shibata K, Kikkawa F, et al: Possible role of Placental Leucine Aminopeptidase in the antiproliferative effect of oxytocin in human endometrial adenocarcinoma. Clin Cancer Res 2003;9:1528-1534.
23. Motzer RJ, Sheinfeld J, Mazumdar M, et al: Paclitaxel, ifosfamide, and cisplatin secondline therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 2000;18:2413-2418.
24. Roggia C, Ukena C, Bohm M, Kilter H: Hepatocyte growth factor (HGF) enhances cardiac commitment of differentiating embryonic stem cells by activating PI3 kinase. Exp Cell Res 2007;313:921-930.
25. Liu H, Harris TM, Kim HH, Childs G: Cardiac myocyte differentiation: the Nkx2.5 and Cripto target genes in P19 clone 6 cells. Funct Integr Genomics 2005;5:218-239.
26. Nagel S, Kaufmann M, Drexler HG, MacLeod RA: The cardiac homeobox gene NKX2-5 is deregulated by juxtaposition with BCL11B in pediatric T-ALL cell lines via a novel t(5;14)(q35.1;q32.2). Cancer Res 2003;63:5329-5334.
27. Kwabi-Addo B, Chung W, Shen L, et al: Age-related DNA methylation changes in normal human prostate tissues. Clin Cancer Res 2007;13:3796-3802.